Mangalam Drugs and Organics Ltd

Shares of Mangalam Drugs and Organics Ltd plunged sharply on 19 Mar 2026, hitting the lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical micro-cap witnessed a maximum daily loss of 4.77%, closing at ₹29.16, reflecting a significant investor sell-off amid deteriorating market sentiment and weak technical indicators.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 19 March 2026, providing investors with the latest insights into its performance and outlook.

Mangalam Drugs and Organics Ltd witnessed a robust surge in its share price on 6 Mar 2026, hitting the upper circuit limit of 5%, closing at ₹32.26. This sharp rally was driven by intense buying interest, resulting in the stock outperforming its sector and broader market indices despite subdued investor participation and regulatory trading restrictions.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Mangalam Drugs and Organics Ltd witnessed a robust surge in its share price on 5 Mar 2026, hitting the upper circuit limit of 5% to close at ₹30.73. This sharp rally was driven by intense buying interest, resulting in the stock outperforming its sector and broader market indices despite subdued investor participation and a regulatory freeze on further price movement.

Mangalam Drugs and Organics Ltd witnessed a robust surge in its share price on 4 Mar 2026, hitting the upper circuit limit of 5% and closing at ₹29.25. This sharp rally was driven by intense buying interest, resulting in a maximum daily gain of 4.97%, significantly outperforming its sector and benchmark indices despite opening with a gap down.

Shares of Mangalam Drugs and Organics Ltd plunged to their lower circuit limit on 2 Mar 2026, succumbing to intense selling pressure that saw the stock lose nearly 5% in a single session. The pharmaceutical company’s shares closed at ₹28.30, marking a significant intraday decline amid heightened volatility and unfilled supply, signalling growing investor apprehension in the micro-cap segment.

Shares of Mangalam Drugs and Organics Ltd plunged to their lower circuit limit on 25 Feb 2026, reflecting intense selling pressure and panic among investors. The stock recorded a maximum daily loss of 4.97%, closing at ₹29.08, down ₹0.87 from the previous close, as unfilled supply overwhelmed demand in a micro-cap pharmaceutical sector stock already under significant bearish sentiment.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 17 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shares of Mangalam Drugs and Organics Ltd plunged to their lower circuit limit on 6 Feb 2026, closing at ₹32.5, down 5.0% on the day. The stock faced intense selling pressure, with volumes concentrated near the day’s low, signalling panic selling and unfilled supply. This marks the third consecutive day of declines, with the stock losing over 14% in that period, significantly underperforming its sector and the broader market.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 February 2026, providing investors with the latest insights into the stock’s performance and outlook.

Mangalam Drugs and Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 5 Feb 2026, hitting its lower circuit price limit of ₹34.21. The stock closed with a maximum daily loss of 5.0%, reflecting intense selling pressure and panic among investors amid subdued market sentiment and deteriorating technical indicators.

Shares of Mangalam Drugs and Organics Ltd plunged to their lower circuit limit on 4 February 2026, closing at ₹36.01, down 4.99% on the day. The stock faced intense selling pressure, with volumes surging and the price hitting the maximum permissible daily loss, reflecting mounting investor concerns amid a deteriorating outlook.

Mangalam Drugs and Organics Ltd surged to its upper circuit limit on 3 February 2026, propelled by robust buying interest and significant investor participation. The stock closed at ₹37.90, marking a 4.99% gain on the day, outperforming its sector and the broader market indices.

Mangalam Drugs and Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 2 Feb 2026, hitting its lower circuit price limit of ₹32.68. The stock endured intense selling pressure, culminating in a maximum daily loss of 4.97%, marking its ninth consecutive day of decline and signalling mounting investor panic amid deteriorating fundamentals.

Mangalam Drugs and Organics Ltd witnessed a sharp decline on 1 Feb 2026, hitting its lower circuit limit of 5%, closing at ₹34.39. The stock faced intense selling pressure, marking its eighth consecutive day of losses and underperforming the Pharmaceuticals & Biotechnology sector by over 5% today.

Mangalam Drugs and Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 30 Jan 2026, hitting its lower circuit price limit of ₹36.20. The stock endured intense selling pressure, closing with a maximum daily loss of 4.99%, marking its seventh consecutive day of decline and signalling heightened investor anxiety.